Voronoi
Voronoi Inc is a South Korean clinical-stage biopharmaceutical company focused on discovering targeted small molecule therapeutics for precision oncology and rare genetic diseases. The company utilizes its proprietary Voronomics drug discovery platform to engineer highly selective kinase inhibitors targeting lung cancer, breast cancer, and autoimmune conditions. Principal revenue is derived from upfront licensing fees, strategic research collaborations, and clinical milestone payments from global biopharmaceutical partners. Core end markets serve oncology treatment centers, precision medicine clinics, and global drug development corporations. Voronoi holds an innovative position in South Korea's biopharmaceutical sector for precision small molecule kinase inhibitor drug discovery. The company is headquartered in Incheon, South Korea, and its shares trade on the KOSDAQ market of the Korea Exchange.
2 of the funds FundTelligence covers report a position in Voronoi.
- Legal name
- VORONOI INC
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 2
Funds holding Voronoi
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)